Akihiro Yoshii

692 total citations
27 papers, 593 citations indexed

About

Akihiro Yoshii is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Akihiro Yoshii has authored 27 papers receiving a total of 593 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Pulmonary and Respiratory Medicine, 10 papers in Oncology and 7 papers in Molecular Biology. Recurrent topics in Akihiro Yoshii's work include Lung Cancer Treatments and Mutations (10 papers), Lung Cancer Diagnosis and Treatment (7 papers) and Lung Cancer Research Studies (6 papers). Akihiro Yoshii is often cited by papers focused on Lung Cancer Treatments and Mutations (10 papers), Lung Cancer Diagnosis and Treatment (7 papers) and Lung Cancer Research Studies (6 papers). Akihiro Yoshii collaborates with scholars based in Japan and Vietnam. Akihiro Yoshii's co-authors include Kunio Dobashi, Kunihiko Iizuka, Tsugio Nakazawa, Masatomo Mori, Takeo Horie, Takashi Harada, Hideo Tsukagoshi, Tamotsu Ishizuka, Yasuo Shimizu and Yoshio Tomizawa and has published in prestigious journals such as The Journal of Physiology, Annals of Oncology and British Journal of Pharmacology.

In The Last Decade

Akihiro Yoshii

26 papers receiving 577 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Akihiro Yoshii Japan 13 335 162 150 125 55 27 593
Weiping Qiu United States 10 226 0.7× 82 0.5× 68 0.5× 59 0.5× 43 0.8× 16 442
Tristan Pocock United Kingdom 9 323 1.0× 89 0.5× 73 0.5× 42 0.3× 48 0.9× 17 582
Hyacinth Sterling United States 14 624 1.9× 97 0.6× 92 0.6× 128 1.0× 239 4.3× 20 886
Hongliang Luo China 16 316 0.9× 73 0.5× 132 0.9× 140 1.1× 58 1.1× 63 735
Anne Rochat France 12 566 1.7× 87 0.5× 30 0.2× 127 1.0× 43 0.8× 14 735
April M. Hoggatt United States 17 506 1.5× 78 0.5× 62 0.4× 66 0.5× 89 1.6× 33 746
Hung‐Pei Tsai Taiwan 14 287 0.9× 91 0.6× 121 0.8× 66 0.5× 140 2.5× 68 732
Min‐Goo Lee South Korea 10 236 0.7× 69 0.4× 70 0.5× 130 1.0× 22 0.4× 12 438
Gunisha Sagar United States 12 564 1.7× 86 0.5× 94 0.6× 29 0.2× 63 1.1× 14 755
Amir Aghajanian United States 11 295 0.9× 130 0.8× 69 0.5× 76 0.6× 79 1.4× 15 627

Countries citing papers authored by Akihiro Yoshii

Since Specialization
Citations

This map shows the geographic impact of Akihiro Yoshii's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Akihiro Yoshii with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Akihiro Yoshii more than expected).

Fields of papers citing papers by Akihiro Yoshii

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Akihiro Yoshii. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Akihiro Yoshii. The network helps show where Akihiro Yoshii may publish in the future.

Co-authorship network of co-authors of Akihiro Yoshii

This figure shows the co-authorship network connecting the top 25 collaborators of Akihiro Yoshii. A scholar is included among the top collaborators of Akihiro Yoshii based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Akihiro Yoshii. Akihiro Yoshii is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Imai, Hisao, Yoshio Tomizawa, Kyoichi Kaira, et al.. (2020). Phase II Study of Weekly Nanoparticle Albumin-Bound Paclitaxel as Second- or Third-Line Therapy in Patients with Advanced Non-Small Cell Lung Cancer. Chemotherapy. 65(1-2). 21–28. 3 indexed citations
2.
Tamiya, Akihiro, Masahiro Morimoto, Kyoichi Okishio, et al.. (2018). A phase I/II trial of pemetrexed plus radiotherapy in elderly patients with locally advanced non-small cell lung cancer. Investigational New Drugs. 36(4). 667–673. 2 indexed citations
3.
Sakurai, Reiko, Yoshio Tomizawa, Akihiro Yoshii, et al.. (2017). A phase II study of biweekly gemcitabine and carboplatin in completely resected stage IB-IIIA non-small cell lung cancer. Cancer Chemotherapy and Pharmacology. 81(1). 103–109. 5 indexed citations
4.
Kaira, Kyoichi, Yoshio Tomizawa, Hisao Imai, et al.. (2016). Phase I study of nab-paclitaxel plus carboplatin and concurrent thoracic radiotherapy in patients with locally advanced non-small cell lung cancer. Cancer Chemotherapy and Pharmacology. 79(1). 165–171. 14 indexed citations
5.
Imai, Hisao, Keita Mori, Yoshio Tomizawa, et al.. (2015). Clinical impact of postprogression survival for overall survival in elderly patients (aged 75 years or older) with advanced nonsmall cell lung cancer. Journal of Cancer Research and Therapeutics. 11(3). 606–611. 7 indexed citations
6.
Imai, Hisao, Keita Mori, Kyoichi Kaira, et al.. (2014). Surrogate endpoints for overall survival in advanced non-small-cell lung cancer patients with mutations of the epidermal growth factor receptor gene. Molecular and Clinical Oncology. 2(5). 731–736. 19 indexed citations
7.
Kaira, Kyoichi, Yoshio Tomizawa, Akihiro Yoshii, et al.. (2013). Phase II study of oral S-1 plus cisplatin with bevacizumab for advanced non-squamous non-small cell lung cancer. Lung Cancer. 82(1). 103–108. 7 indexed citations
8.
Kaira, Kyoichi, Yoshio Tomizawa, Akihiro Yoshii, et al.. (2013). Phase II study of oral S-1 and cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer. Lung Cancer. 82(3). 449–454. 15 indexed citations
9.
Tomizawa, Yoshio, et al.. (2013). Retrospective Analysis of Re-Challenge of EGFR TK-IS in Patients with Advanced and Recurrent Non-Small Cell Lung Cancer. Annals of Oncology. 24. ix96–ix96. 1 indexed citations
10.
Hoshina, Hiroyuki, et al.. (2012). Synthesis of arsenic graft adsorbents in pilot scale. Radiation Physics and Chemistry. 81(8). 1033–1035. 6 indexed citations
11.
Kaira, Kyoichi, Noriaki Sunaga, Yoshio Tomizawa, et al.. (2009). A phase II study of amrubicin, a synthetic 9-aminoanthracycline, in patients with previously treated lung cancer. Lung Cancer. 69(1). 99–104. 44 indexed citations
12.
Ishizuka, Tamotsu, Akihiro Yoshii, Takeshi Hisada, et al.. (2002). Effects of Fluticasone Propionate on Bone Mineral Density in Patients with Persistent Bronchial Asthma.. Internal Medicine. 41(10). 798–804. 6 indexed citations
13.
Iizuka, Kunihiko, et al.. (2001). A highly selective inhibitor of Rho-associated coiled-coil forming protein kinase, Y-27632, prolongs cardiac allograft survival of the BALB/c-to-C3H/He mouse model. The Journal of Heart and Lung Transplantation. 20(9). 956–963. 33 indexed citations
14.
Iizuka, Kunihiko, Yasuo Shimizu, Hideo Tsukagoshi, et al.. (2000). Evaluation of Y-27632, a Rho-kinase inhibitor, as a bronchodilator in guinea pigs. European Journal of Pharmacology. 406(2). 273–279. 67 indexed citations
15.
Yoshii, Akihiro, Kunihiko Iizuka, Kunio Dobashi, et al.. (1999). Relaxation of Contracted Rabbit Tracheal and Human Bronchial Smooth Muscle by Y-27632 through Inhibition of Ca2 + Sensitization. American Journal of Respiratory Cell and Molecular Biology. 20(6). 1190–1200. 138 indexed citations
16.
Dobashi, Kunio, et al.. (1999). Effect of β-Agonists on Production of Cytokines by Activated T Cells Obtained from Asthmatic Patients and Normal Subjects. Journal of Asthma. 36(7). 619–626. 2 indexed citations
17.
Iizuka, Kunihiko, Akihiro Yoshii, Hideo Tsukagoshi, et al.. (1999). A major role for the Rho‐associated coiled coil forming protein kinase in G‐protein‐mediated Ca2+ sensitization through inhibition of myosin phosphatase in rabbit trachea. British Journal of Pharmacology. 128(4). 925–933. 97 indexed citations
18.
Horie, Takeo, Kunio Dobashi, Kunihiko Iizuka, et al.. (1999). Interferon-γ rescues TNF-α-induced apoptosis mediated by up-regulation of TNFR2 on EoL-1 cells. Experimental Hematology. 27(3). 512–519. 23 indexed citations
19.
Iizuka, Kunihiko, et al.. (1998). InsP3, but not novel Ca2+ releasers, contributes to agonist‐initiated contraction in rabbit airway smooth muscle. The Journal of Physiology. 511(3). 915–933. 25 indexed citations
20.
Iizuka, Kunihiko, et al.. (1997). Receptor-dependent G protein-mediated Ca2+ sensitization in canine airway smooth muscle. Cell Calcium. 22(1). 21–30. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Weiping Qiu Breakdown of academic impact, for papers by Tristan Pocock Breakdown of academic impact, for papers by Hyacinth Sterling Breakdown of academic impact, for papers by Hongliang Luo Breakdown of academic impact, for papers by Anne Rochat Breakdown of academic impact, for papers by April M. Hoggatt Breakdown of academic impact, for papers by Hung‐Pei Tsai Breakdown of academic impact, for papers by Min‐Goo Lee Breakdown of academic impact, for papers by Gunisha Sagar Breakdown of academic impact, for papers by Amir Aghajanian
Rankless by CCL
2026